Erkan D, Asherson R A, Espinosa G, Cervera R, Font J, Piette J-C, Lockshin M D
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA.
Ann Rheum Dis. 2003 Jun;62(6):530-3. doi: 10.1136/ard.62.6.530.
Catastrophic antiphospholipid syndrome (APS) is defined as life threatening multiple organ thromboses developing simultaneously or over a short period. The survival rate of catastrophic APS is about 50%, but the long term outcome of patients who survive is unknown.
To determine the long term outcome of patients with catastrophic APS and provide further information on patients who survived.
The clinical characteristics and outcomes of 130 patients with catastrophic APS have been reported previously. Six new cases were recently added to this series. Based on these publications, the authors who reported patients who had survived were contacted. Each author was asked (a) what treatment they gave their patients after the catastrophic APS; (b) if their patients had any further thrombosis.
63/136 (46%) patients died at the initial event. Of the remaining 73 patients, information was available for 58 (79%). Thirty eight (66%) patients did not develop further APS related events during an average follow up of 67.2 months. Eleven (19%) patients developed further APS related events but were still alive. No patients developed further catastrophic APS. Nine (16%) patients died: due to multiple organ failure (three patients); myelofibrosis (one); pneumonia (one); and APS related events (four).
Sixty six per cent of patients who survive an initial catastrophic APS event remained symptom free with anticoagulation during an average follow up of 67.2 months. Twenty six per cent of the survivors developed further APS related events and the mortality rate of these patients was about 25%.
灾难性抗磷脂综合征(APS)定义为在短时间内同时发生或出现危及生命的多器官血栓形成。灾难性APS的生存率约为50%,但存活患者的长期预后尚不清楚。
确定灾难性APS患者的长期预后,并提供关于存活患者的更多信息。
先前已报道130例灾难性APS患者的临床特征和预后。本系列最近新增6例。基于这些报道,与报道存活患者的作者取得联系。每位作者被问及:(a)在灾难性APS发生后他们给予患者何种治疗;(b)他们的患者是否有进一步的血栓形成。
63/136(46%)例患者在初次发病时死亡。其余73例患者中,58例(79%)有可用信息。在平均67.2个月的随访期间,38例(66%)患者未发生进一步的APS相关事件。11例(19%)患者发生了进一步的APS相关事件,但仍存活。无患者发生进一步的灾难性APS。9例(16%)患者死亡,原因分别为多器官功能衰竭(3例)、骨髓纤维化(1例)、肺炎(1例)和APS相关事件(4例)。
在初次灾难性APS事件中存活的患者,66%在平均67.2个月的抗凝随访期间无症状。26%的幸存者发生了进一步的APS相关事件,这些患者的死亡率约为25%。